



RECEIVED

APR 22 2002

PATENT

Attorney Docket No: 01017/36524A

CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Boylan et al.

Application Serial No. 09/909,474

Filed: July 19, 2001

For: Novel Serine Threonine Kinase
Member, h2520-59

Group Art Unit: 1633

Examiner: To be assigned

) I hereby certify that this paper is being
) deposited with the United States Postal
) Service with sufficient postage as first
) class mail, postage prepaid, in an
) envelope addressed to: Commissioner for
) Patents, Washington, D.C., 20231 on this
) date:

) March 11, 2002

RECEIVED

APR 22 2002

) *Thomas A. Cawley, Jr.*
) Thomas A. Cawley, Jr., Ph.D.
) Reg. No. 40,994
) Attorney for Applicants

#9
H.9
5/16/02

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the examiner the enclosed publications, as listed on the attached Form PTO-1449, which may be considered material to the examination of the above-identified patent application. Document B1 is 2,352 pages, and is therefore enclosed on compact disc.

This information disclosure statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This information disclosure statement is submitted before receipt of a first official action on the merits and consequently should be considered by the Patent Office without payment of a fee [see 37 C.F.R. §1.97(b)]. However, should the Patent Office determine that a fee is due for consideration of this information disclosure statement and accompanying

publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855.

Respectfully submitted,


MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:



Thomas A. Cawley, Jr., Ph.D.
Reg. No.: 40,994

March 11, 2002

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 01017/36524A	Serial No. 09/909,474
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant Boylan et al.		
		Filing Date 7-19-01	Group 1633	

RECEIVED
 APR 22 2001
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 00/55350 (2352 pages enclosed on compact disc)	09/21/00	PCT				
	B2	WO 00/08180	02/17/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C1	Hanks <i>et al.</i> , "The protein kinase family: conserved features and deduced phylogeny of the catalytic domains", <i>Science</i> 241:42-52, 1988.	
C2	Cross <i>et al.</i> , "Serine/threonine protein kinases and apoptosis", <i>Exp Cell Res</i> 256:34-41, 2000.	
C3	Mayumi-Matsuda <i>et al.</i> , "Identification of a novel kinase-like gene induced during neuronal cell death", <i>Biochem Biophys Res Comm</i> 258: 260-264, 1999.	
C4	Database GenBank. National Library of Medicine, (Bethesda, Maryland, US), AN AL034548, Blakey, Human DNA sequence from clone RP5-1103G7 on chromosome 20p12.2-13, 2001.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

